Article Contents ::
- 1 The Brand Name CELONIB Has Generic Salt :: IMATINIB
- 2 CELONIB Is From Company CELON(VIVILON) Priced :: Rs. 900.00/3200.00
- 3 CELONIB have IMATINIB is comes under Sub class #N/A of Main Class #N/A
- 4 Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
The Brand Name CELONIB Has Generic Salt :: IMATINIB
CELONIB Is From Company CELON(VIVILON) Priced :: Rs. 900.00/3200.00
CELONIB have IMATINIB is comes under Sub class #N/A of Main Class #N/A
Main Medicine Class:: #N/A Sub Medicine Class :: #N/A
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Chronic myeloid leukaemia, Acute lymphoblastic leukaemia, Myelodysplastic disease, Hypereosinophilic syndrome, Mastocytosis, Dermatofibrosarcoma protuberans, Malignant gastrointestinal stromal tumours
Drug Dose ::
Adult: PO Chronic myeloid leukaemia Chronic phase: 400 mg/day, up to 600 mg/day. Blast crisis or aceelerated phase: 600 mg/day, up to 400 mg twice daily if needed. Acute lymphoblastic leukaemia; Monotherapy in relapsed or refractory acute lymphoblastic leukaemia 600 mg/day w/ induction, maintenance or consolidation therapy. Hypereosinophilic syndrome; Myelodysplastic disease 400 mg/day. Unresectable, metastatic GI stromal tumours 400 or 600 mg/day. Mastocytosis 400 mg/day. Start w/ 100 mg/day if there is associated eosinophilia. Dermatofibrosarcoma protuberans 400 mg twice daily.
Drug Precautions ::
Cardiac disease or increased risk for CHF. Monitor for signs of severe fluid retention. Monitor CBC regularly. Renal and hepatic impairment. Monitor LFTs. Pregnancy.
Drug Side Effects ::
Fluid retention/oedema, nausea and vomiting, muscle cramps, musculoskeletal pain, diarrhoea, rash. Fatigue, asthenia, headache, dizziness, insomnia, depression, anxiety, joint pain, arthralgia, myalgia, back pain, abdominal pain, flatulence, dyspepsia, loose stools, anorexia, constipation, taste disturbance, nasopharyngitis, cough, pharyngolaryngeal pain, pharyngitis, sinusitis, upper respiratory tract infection, pneumonia, influenza, dyspnoea, haemorrhage, pyrexia, increased wt, night sweats, rigors, hepatotoxi
Pregnancy category ::
Drug Mode of Action ::
Imatinib, is a tyrosine kinase inhibitor that inhibits the BCR-ABL tyrosine kinase created by the Philadelphia chromosome abnormality in chronic myeloid leukaemia (CML). It blocks proliferation and induces apoptosis in BCR-ABL positive cell lines, as well as fresh leukaemic cells from Philadelphia chromosome positive CML. Imatinib also inhibits receptor kinases for platelet-derived growth factor (PDGF) and stem cell factor (SCF), c-kit, PDGF- and SCF-mediated cellular events.
Drug Interactions ::
Increased serum levels w/ CYP3A4 inhibitors (e.g. azole antifungals, macrolide antibiotics). Reduced serum levels w/ CYP3A4 inducers (e.g. carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampicin). May increase serum levels of substrates of CYP3A4 (e.g. ciclosporin, pimozide, triazolo-benzodiazepines, dihydropyridine Ca channel blockers, certain statins), CYP2C9 (e.g. warfarin) and CYP2D6.